Cure8 trial brief
This study will collect real-world data on adults with moderate-to-severe ulcerative colitis who start upadacitinib, tracking symptom remission and imaging response over one to two years — information that can help patients and clinicians understand how the drug performs outside randomized trials.
Adults with ulcerative colitis considering or prescribed upadacitinib; gastroenterologists and IBD clinicians; researchers interested in real-world outcomes of JAK inhibitors.
This is an observational (non-interventional) registry study — upadacitinib is prescribed by the treating physician according to local label, and the study collects routinely obtained clinical data and imaging without adding extra procedures.
The main outcomes focus on symptomatic remission by adapted partial Mayo score and proportions who maintain response at 52 weeks; intestinal ultrasound (IUS) response at week 8 is included as an early marker. The record excludes people previously exposed to a JAK inhibitor.
Because it’s observational, the study will describe outcomes in real-world treated patients rather than testing the drug in a randomized trial. Data may help characterize how patients prescribed upadacitinib do over 1–2 years in routine clinical settings across multiple centers.
This is an observational registry (ACTIVE_NOT_RECRUITING) where treatment decisions are made by physicians per local label; it does not randomize or assign treatment. The study excludes prior JAK inhibitor exposure. As an observational study, results will be descriptive and may be influenced by prescribing patterns and baseline differences between patients.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This trial tests whether raising the upadacitinib dose to 45 mg can recapture clinical response in people with ulcerative colitis who lost response on the 30 mg maintenance dose. If effective and safe, the approach could...
Lower hospitalization rates suggest upadacitinib may reduce severe disease events that require inpatient care, which matters to patients and clinicians aiming to avoid hospital stays and complications. Large real-world...
This analysis summarizes longer-term safety data for upadacitinib (Rinvoq) in people with moderate to severe ulcerative colitis and Crohn’s disease.
